Home/Filings/4/0001104659-21-126728
4//SEC Filing

Scheessele William John 4

Accession 0001104659-21-126728

CIK 0001818382other

Filed

Oct 14, 8:00 PM ET

Accepted

Oct 15, 3:51 PM ET

Size

5.5 KB

Accession

0001104659-21-126728

Insider Transaction Report

Form 4
Period: 2021-10-13
Scheessele William John
Chief Commercial Officer
Transactions
  • Award

    Stock Options (right to buy)

    2021-10-13+157,558157,558 total
    Exercise: $10.03Exp: 2031-10-13Common Stock (157,558 underlying)
Footnotes (1)
  • [F1]The first 25% of the option becomes exercisable on August 9, 2022, after which 1/36 of the option will become exercisable on the 9th of each month through August 9, 2025.

Issuer

Humacyte, Inc.

CIK 0001818382

Entity typeother

Related Parties

1
  • filerCIK 0001879378

Filing Metadata

Form type
4
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 3:51 PM ET
Size
5.5 KB